By John Harbison|2017-10-24T15:57:11-08:00October 24, 2017|Tech Coast Angels Portfolio Companies in the Press|Comments Off on Cognition Therapeutics Announces Issuance of Broad Composition of Matter Patent for CT1812, a First-in-Class Alzheimer’s Disease Clinical Candidate
